Evidence map›Paper›PMID 32138377›Full record

ReviewPharmaceuticals (Basel, Switzerland)2020

[

Ute Hennrich, Martina Benešová

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Correlation of [EJNMMI research · 2026
    Article
  3. Article
  4. Review
  5. Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  6. Article
  7. Review
  8. ScalableWorld journal of nuclear medicine · 2026
    Article
  9. Looking backward to move forward: a chemist's perspective on the future of radiopharmaceuticals.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Article
  10. Article
  11. Article
  12. Combined SSTR2-targeted Analogue withFrontiers in oncology · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. False Positive Findings ofMolecular imaging and radionuclide therapy · 2025
    Article
  17. Article
  18. Optimized Automated Cassette-Based Synthesis of [Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ute HennrichDivision of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.ORCID 0000-0003-4198-1899
Martina BenešováMolecular Biology of Systemic Radiotherapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
German Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the United States, [

Indexed as

[68Ga]Ga-DOTA-TOCneuroendocrine tumors (NETs)positron emission tomography (PET)somatostatin receptor (SSTR)theranostics

Identifiers

PMID32138377
PMCPMC7151717
OpenAlexW3010281214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.